Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021

NCT04939350 | Completed

• 1 other identifier: 2021-A00343-38
• Study Type: observational
• Target: 742
• Locations: 1 country
• Sites: 1

Brief Summary

the purpose of this study is to estimate vacinal coverage against hepatitis A and B viruses, pneumococcus, diphtheria/tetanos and poliomyelitis, influenza virus and covid in cirrhotic patients followed in general hospitals of France and to show the

Conditions

Cirrhosis

Keywords

Vaccinal coverage; vaccination; cirrhosis; cirrhotic; COVID; hepatitis B; hepatitis A; influenzae virus; pneumococcus; tetanus; poliomyelitis

Outcome Measures

Primary Outcomes (1)

• percentage fully immunization coverage

  percentage of patients fully vaccinated against polio DT, seasonal influenza, HAV, HBV, pneumococcal and COVID19 in our sample

  Day 0

Secondary Outcomes (6)

• percentage DTpolio immunization coverage

  Day 0

• percentage HAV immunization coverage

  Day 0

• percentage HBV immunization coverage

  Day 0

• percentage Pneumococcal immunization coverage

  Day 0

• percentage Influenza virus immunization coverage

  Day 0

Interventions

questionnaire OTHER

patients will complete a vaccination questionnaire

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All cirrhotic patients followed for at least 6 months in consultation or hospitalization during the duration of the study in the general hospitals members of the ANGH participating in the study.

You may qualify if:

• adult patient
• histologically proven or asserted cirrhosis on a combination of clinical, biological, endoscopic and radiological criteria
• follow-up of cirrhosis \> 6 months
• subject informed of the study and not having objected to it.

You may not qualify if:

• immunosuppression not related to liver disease: HIV, variable common immune deficiency, chemotherapy, anatomical splenectomy, immunosuppressive treatments for non-hepatic disease
• vaccine contraindication.

Sponsors & Collaborators

• Centre Hospitalier Sud Francilien: lead

Study Sites (1)

Centre Hospitalier Sud Francilien

Corbeil-Essonnes, France, 91106, France

Location

MeSH Terms

Conditions

Fibrosis; Hepatitis B; Hepatitis A; Tetanus; Poliomyelitis

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Blood-Borne Infections; Communicable Diseases; Infections; Hepadnaviridae Infections; DNA Virus Infections; Virus Diseases; Hepatitis, Viral, Human; Hepatitis; Liver Diseases; Digestive System Diseases; Enterovirus Infections; Picornaviridae Infections; RNA Virus Infections; Clostridium Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Myelitis; Central Nervous System Infections; Central Nervous System Diseases; Nervous System Diseases; Spinal Cord Diseases; Neuroinflammatory Diseases; Neuromuscular Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 15, 2021
• First Posted: June 25, 2021
• Study Start: September 27, 2021
• Primary Completion: December 27, 2022
• Study Completion: December 27, 2022
• Last Updated: May 22, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)